Capmatinib price announced in 2024, what are the new changes?

Capmatinib is an innovative targeted therapy drug used to treat non-small cell lung cancer (NSCLC). As a MET (tyrosine kinase) inhibitor, capmatinib was developed to target patients with abnormal expression or activation of the MET pathway, which plays a key role in some NSCLC patients.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.

METis an important protein involved in regulating cell growth and differentiation. However, in cancer, abnormal activation of the MET pathway may lead to abnormal proliferation and spread of tumor cells. Capmatinib effectively blocks abnormal cell signaling by selectively inhibiting the activity of MET kinase, thereby inhibiting the growth of NSCLC.

Capmatinib is usually given as an oral medication, allowing patients to take treatment conveniently at home. This drug has shown significant efficacy in clinical trials, especially for those patients with abnormal MET NSCLC, bringing new hope for treatment.

When using capmatinib, patients need to closely cooperate with their doctor's guidance and receive regular medical monitoring. Medications may be associated with some side effects, including but not limited to fatigue, nausea, high blood pressure, etc., so patients need to report any discomfort symptoms to their doctor in a timely manner.